Bupropion in Pregnancy
Bupropion can be used during pregnancy when clinically indicated, as it does not appear to be associated with major congenital malformations or significant adverse obstetrical outcomes overall, though caution is advised regarding small potential increases in specific cardiovascular defects.
Safety Profile
According to the most recent 2024 AJOG guidelines, bupropion does not seem to be associated with major congenital malformations or other significant adverse obstetrical outcomes, although data are limited 1. The FDA drug label similarly states that epidemiological studies of pregnant women exposed to bupropion in the first trimester have not identified an increased risk of congenital malformations overall 2.
Specific Cardiovascular Concerns
The evidence shows two specific cardiovascular malformations with small absolute risk increases associated with first-trimester bupropion monotherapy 1:
- Left ventricular outflow tract obstruction (LVOTO): Incidence 0.279% vs 0.07% with other antidepressants
- Ventricular septal defects (VSD): Adjusted OR 2.9 (95% CI 1.5-5.5)
However, confounding by indication cannot be ruled out, and other studies have not consistently found these associations 1. The FDA label notes that study findings on LVOTO are inconsistent and do not allow definitive conclusions 2.
Other Potential Risks
- Diaphragmatic hernia: One study suggested possible increased risk (aOR 2.77; 95% CI 1.34-5.71), but the absolute risk remains extremely small given the rarity of this condition (population prevalence 0.012%-0.031%), and other studies have not replicated this finding 1
- Spontaneous abortion: Possible increased risk, but confounding by indication cannot be excluded 1
- Poor neonatal adaptation: Only one case report of seizures due to severe hyperinsulinism 1
Clinical Decision-Making Algorithm
When to Consider Bupropion
Bupropion is particularly appropriate for pregnant patients requiring treatment for:
- Depression that has not responded adequately to behavioral interventions
- Co-occurring depression and smoking cessation needs
- Patients who cannot tolerate or have failed other antidepressants
- ADHD when stimulants must be avoided (though less efficacious than stimulants) 1
When to Exercise Greater Caution
The 2015 USPSTF guidelines note that bupropion is pregnancy category C (animal studies show adverse effects but no adequate human studies) 3. However, this must be balanced against the significant risks of untreated maternal depression, including increased risk of relapse when antidepressants are discontinued during pregnancy 2.
Dosing Recommendations
Standard dosing from 2024 AJOG guidelines 1:
Sustained Release (SR):
- Starting dose: 100-150 mg PO daily
- Maintenance dose: 100-150 mg PO twice daily
Extended Release (XL):
- Starting dose: 150 mg PO daily
- Maintenance dose: 150-300 mg PO daily
- Maximum dose: 450 mg per day
Monitoring During Pregnancy
Specific monitoring recommendations when using bupropion 1:
- Monitor pregnancy carefully, including fetal growth assessments
- Blood pressure checks (given cardiovascular concerns)
- Ensure appropriate maternal weight gain
- Consider fetal echocardiography if first-trimester exposure occurred, given the small increased risk of cardiac malformations
Breastfeeding Considerations
Caution is advised during breastfeeding 1:
- Very limited data (21 cases)
- Bupropion is present in human milk and has been detected in infant serum at very low levels (sometimes undetectable)
- Generally no adverse events reported
- Two case reports of seizures in breastfed infants exist, warranting careful monitoring
Comparative Context
The 2024 guidelines note that switching from stimulants to bupropion in the perinatal period is a reasonable option, particularly for individuals requiring treatment for co-occurring depression, given the available safety data 1. However, clinicians should recognize that bupropion is not as efficacious as stimulants for ADHD treatment.
Key Clinical Pitfalls to Avoid
Do not automatically discontinue bupropion upon pregnancy recognition if the patient requires it for daily functioning—untreated maternal depression carries significant risks 2
Do not use bupropion as monotherapy for smoking cessation in pregnancy without considering behavioral interventions first, as the USPSTF found insufficient evidence for pharmacotherapy effectiveness in pregnant smokers 3
Do not ignore the seizure risk—bupropion lowers seizure threshold, so avoid in patients with seizure disorders or eating disorders 2
Engage in shared decision-making that weighs the small absolute risks of specific cardiac malformations against the substantial risks of untreated maternal psychiatric illness 3